Skip to contentL
Ligand Pharmaceuticals Inc
L
LGNDLigand Pharmaceuticals Inc Q3 2023 · 10-Q
Revenue$32.87M$32.87M−44.5% vs Q3 2022 Net Income-$10.27M-$10.27MN/M vs Q3 2022 EPS Diluted-$0.59-$0.59N/M vs Q3 2022 Operating Income$3,078,000−75.1% Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Ligand Pharmaceuticals Inc · CIK 886163 · Engraved from SEC EDGAR
derived
Free Cash Flowderived$7,159,000−55.7% Margins · derivedOperating margin9.4%−11.5 pt vs Q3 2022
Net margin-31.3%−31.9 pt vs Q3 2022
ended Sep 30, 2023 · filed Nov 9, 2023 · 40 d after period end